Changes to the Code
S. 1637 · Medicaid VBPs for Patients Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
MVP Act
In committee · step 2 of 5
42 U.S.C. § 1320a–7b Criminal penalties for acts involving Federal health care programs
3 changes the bill asks for here, 3 carried out
- Carried out:
by striking
and
at the end; - Carried out:
in subparagraph (L)(iii), by striking the period and inserting
; and
; and - Carried out:
by adding at the end the following new subparagraph:
(M) any remuneration provided by a manufacturer or third party on behalf of a manufacturer to a State under a value-based purchasing arrangement (as defined in section 1927(k)(12)) under a State plan under title XIX (or waiver of such plan) in the case a patient fails to achieve …
§ 1320a–7b(b)(3)Paragraphs (1) and (2) shall not apply to—(J)–(L)
Start of § 1320a–7b to (b)(3)(I) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (J) | (J) | (J) | ||
| a discount in the price of an applicable drug (as defined in paragraph (2) of section 1395w–114a(g) of this title) of a manufacturer that is furnished to an applicable beneficiary (as defined in paragraph (1) of such section) under the Medicare coverage gap discount program under section 1395w–114a of this title; | a discount in the price of an applicable drug (as defined in paragraph (2) of section 1395w–114a(g) of this title) of a manufacturer that is furnished to an applicable beneficiary (as defined in paragraph (1) of such section) under the Medicare coverage gap discount program under section 1395w–114a of this title; | |||
| (K) | (K) | (K) | ||
| an incentive payment made to a Medicare fee-for-service beneficiary by an ACO under an ACO Beneficiary Incentive Program established under subsection (m) of section 1395jjj of this title, if the payment is made in accordance with the requirements of such subsection and meets such other conditions as the Secretary may establish; | an incentive payment made to a Medicare fee-for-service beneficiary by an ACO under an ACO Beneficiary Incentive Program established under subsection (m) of section 1395jjj of this title, if the payment is made in accordance with the requirements of such subsection and meets such other conditions as the Secretary may establish; | |||
| (L) | (L) | (L) | ||
| a bona fide mental health or behavioral health improvement or maintenance program, if— | a bona fide mental health or behavioral health improvement or maintenance program, if— | |||
| (L)(i) | (i) | (i) | ||
| such program— | such program— |
§ 1320a–7b(b)–(c)
(b)(3)(L)(i)(I)–(ii)(V) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b)(3)(L)(ii)(VI) | (VI) | (VI) | ||
| any similar entity, as determined by the Secretary; and | any similar entity, as determined by the Secretary; and | |||
| (b)(3)(L)(iii) | (iii) | (iii) | ||
| neither the provision of such program, nor the value of such program, are contingent upon the number or value of referrals made by a physician or other clinician to such entity or the amount or value of other business generated by such physician for the entity | neither the provision of such program, nor the value of such program, are contingent upon the number or value of referrals made by a physician or other clinician to such entity or the amount or value of other business generated by such physician for the entity[inserted: ; and] | |||
| (b)(3)(M) | (M) [inserted: ] | |||
| [inserted: any remuneration provided by a manufacturer or third party on behalf of a manufacturer to a State under a value-based purchasing arrangement (as defined in section 1927(k)(12)) under a State plan under title XIX (or waiver of such plan) in the case a patient fails to achieve outcomes or measures defined in such arrangement following the administration of a covered outpatient drug (as defined in section 1927(k)(2)).] | ||||
| (b)(4) | (4) | (4) | ||
| Whoever without lawful authority knowingly and willfully purchases, sells or distributes, or arranges for the purchase, sale, or distribution of a beneficiary identification number or unique health identifier for a health care provider under subchapter XVIII, subchapter XIX, or subchapter XXI shall be imprisoned for not more than 10 years or fined not more than $500,000 ($1,000,000 in the case of a corporation), or both. | Whoever without lawful authority knowingly and willfully purchases, sells or distributes, or arranges for the purchase, sale, or distribution of a beneficiary identification number or unique health identifier for a health care provider under subchapter XVIII, subchapter XIX, or subchapter XXI shall be imprisoned for not more than 10 years or fined not more than $500,000 ($1,000,000 in the case of a corporation), or both. | |||
| (c) | (c) False statements or representations with respect to condition or operation of institutions | (c) False statements or representations with respect to condition or operation of institutions | ||
| Whoever knowingly and willfully makes or causes to be made, or induces or seeks to induce the making of, any false statement or representation of a material fact with respect to the conditions or operation of any institution, facility, or entity in order that such institution, facility, or entity may qualify (either upon initial certification or upon recertification) as a hospital, critical access hospital, skilled nursing facility, nursing facility, intermediate care facility for the mentally retarded, home health agency, or other entity (including an eligible organization under section 1395mm(b) of this title) for which certification is required under subchapter XVIII or a State health care program (as defined in section 1320a–7(h) of this title), or with respect to information required to be provided under section 1320a–3a of this title, shall be guilty of a felony and upon conviction thereof shall be fined not more than $100,000 or imprisoned for not more than 10 years, or both. | Whoever knowingly and willfully makes or causes to be made, or induces or seeks to induce the making of, any false statement or representation of a material fact with respect to the conditions or operation of any institution, facility, or entity in order that such institution, facility, or entity may qualify (either upon initial certification or upon recertification) as a hospital, critical access hospital, skilled nursing facility, nursing facility, intermediate care facility for the mentally retarded, home health agency, or other entity (including an eligible organization under section 1395mm(b) of this title) for which certification is required under subchapter XVIII or a State health care program (as defined in section 1320a–7(h) of this title), or with respect to information required to be provided under section 1320a–3a of this title, shall be guilty of a felony and upon conviction thereof shall be fined not more than $100,000 or imprisoned for not more than 10 years, or both. | |||
Rest of § 1320a–7b unchanged
42 U.S.C. § 1395w–3a Use of average sales price payment methodology
2 changes the bill asks for here, 2 carried out
- Carried out:
by striking In calculating and inserting the following:(A) In general.— Subject to subparagraph (B), in calculating; and
- Carried out:
by adding at the end the following new subparagraph:
(B) Certain remuneration under value-based purchasing arrangements excluded.— In calculating the manufacturer’s average sales price under this subsection for a drug or biological that is sold under a value-based purchasing arrangement (as defined in section 1927(k)(12)) and with …
§ 1395w–3a(c)Manufacturer’s average sales price(2)–(4)
Start of § 1395w–3a to (c)(2)(A) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (2)(B) | (B) Sales at nominal charge | (B) Sales at nominal charge | ||
| Such other sales as the Secretary identifies as sales to an entity that are merely nominal in amount (as applied for purposes of section 1396r–8(c)(1)(C)(ii)(III) of this title, except as the Secretary may otherwise provide). | Such other sales as the Secretary identifies as sales to an entity that are merely nominal in amount (as applied for purposes of section 1396r–8(c)(1)(C)(ii)(III) of this title, except as the Secretary may otherwise provide). | |||
| (3) | (3) Sale price net of discounts | (3) Sale price net of discounts | ||
| (3)(A) | (A) [inserted: In general.—] | |||
| [inserted: Subject to subparagraph (B), in calculating the manufacturer’s average sales price under this subsection, such price shall include volume discounts, prompt pay discounts, cash discounts, free goods that are contingent on any purchase requirement, chargebacks, and rebates (other than rebates under subsection (i), section 1396r–8 of this title, or section 1395w–114b of this title). For years after 2004, the Secretary may include in such price other price concessions, which may be based on recommendations of the Inspector General, that would result in a reduction of the cost to the purchaser.] | ||||
| (3)(B) | (B) [inserted: Certain remuneration under value-based purchasing arrangements excluded.—] | |||
| [inserted: In calculating the manufacturer’s average sales price under this subsection for a drug or biological that is sold under a value-based purchasing arrangement (as defined in section 1927(k)(12)) and with respect to which the manufacturer of such drug or biological has elected to include multiple best price points (as described in section 1927(c)(1)(C)(ii)(VI)) in reporting the best price of such drug under section 1927(b), such manufacturer's average sales price shall not include any amount that is excluded from the calculation of the average manufacturer price of such drug or biological under section 1927(k)(1)(B)(i)(IX).] | ||||
| (3) | ||||
| (4) | (4) Payment methodology in cases where average sales price during first quarter of sales is unavailable | (4) Payment methodology in cases where average sales price during first quarter of sales is unavailable | ||
| (4)(A) | (A) In general | (A) In general | ||
| Subject to subparagraph (B), in the case of a drug or biological during an initial period (not to exceed a full calendar quarter) in which data on the prices for sales for the drug or biological is not sufficiently available from the manufacturer to compute an average sales price for the drug or biological, the Secretary may determine the amount payable under this section— | Subject to subparagraph (B), in the case of a drug or biological during an initial period (not to exceed a full calendar quarter) in which data on the prices for sales for the drug or biological is not sufficiently available from the manufacturer to compute an average sales price for the drug or biological, the Secretary may determine the amount payable under this section— | |||
Rest of § 1395w–3a unchanged
42 U.S.C. § 1396r–8 Payment for covered outpatient drugs
10 changes the bill asks for here, 8 carried out
- Not carried out:
in subclause (III), by adding a semicolon at the end;
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: adding a semicolon at the end; - Carried out:
in subclause (IV), by striking
and
at the end; - Carried out:
in subclause (V), by striking the period and inserting
; and
; and - Carried out:
by adding at the end the following new subclause:
(VI) may include multiple best price points for a single dosage form and strength of a drug of a manufacturer subject to a value-based purchasing arrangement (as defined in subsection (k)(12)), but only if such manufacturer offers such arrangement to all States..
- Not carried out:
in subclause (IV), by adding a semicolon at the end;
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: adding a semicolon at the end; - Carried out:
in subclause (VII), by striking at the end
and
; - Carried out:
in subclause (VIII), by striking the period at the end and inserting
; and
; and - Carried out:
by adding at the end the following new subclause:
(IX) with respect to a covered outpatient drug that is sold under a value-based purchasing arrangement (as defined in paragraph (12)) during the rebate period, including such a drug that is an inhalation, infusion, instilled, implanted, or injectable drug that is not generally …
- Carried out:
by adding at the end the following new subparagraph:
(D) Special rule for certain value-based purchasing arrangements.— For purposes of subparagraph (A), in determining the average price paid to a manufacturer for a covered outpatient drug that is sold under a value-based purchasing arrangement (as defined in paragraph (12)) that …
- Carried out:
Section 1927(k) of the Social Security Act (42 U.S.C. 1396r–8(k)) is amended by adding at the end the following paragraph:(12) Value-Based Purchasing Arrangement.— The term
value-based purchasing arrangement
has the meaning given such term in section 447.502 of title 42, Code of Federal Regulations (or any successor regulation)..
§ 1396r–8(c)(1)Basic rebate for single source drugs and innovator multiple source drugs(C)–(D)
Start of § 1396r–8 to (c)(1)(C)(ii)(II) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (C)(ii)(III) | (III) | (III) | ||
| shall not take into account prices that are merely nominal in amount3 | shall not take into account prices that are merely nominal in amount3 | |||
| (C)(ii)(IV) | (IV) | (IV) | ||
| in the case of a manufacturer that approves, allows, or otherwise permits any other drug of the manufacturer to be sold under a new drug application approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(c)], shall be inclusive of the lowest price for such authorized drug available from the manufacturer during the rebate period to any manufacturer, wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or governmental entity within the United States, excluding those prices described in subclauses (I) through (IV) of clause (i); | in the case of a manufacturer that approves, allows, or otherwise permits any other drug of the manufacturer to be sold under a new drug application approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(c)], shall be inclusive of the lowest price for such authorized drug available from the manufacturer during the rebate period to any manufacturer, wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or governmental entity within the United States, excluding those prices described in subclauses (I) through (IV) of clause (i); | |||
| (C)(ii)(V) | (V) | (V) | ||
| in the case of a rebate period and a covered outpatient drug that is a selected drug (as referred to in section 1320f–1(c) of this title) during such rebate period, shall be inclusive of the maximum fair price (as defined in section 1320f(c)(3) of this title) for such drug with respect to such period | in the case of a rebate period and a covered outpatient drug that is a selected drug (as referred to in section 1320f–1(c) of this title) during such rebate period, shall be inclusive of the maximum fair price (as defined in section 1320f(c)(3) of this title) for such drug with respect to such period[inserted: ; and] | |||
| (C)(ii)(VI) | (VI) [inserted: ] | |||
| [inserted: may include multiple best price points for a single dosage form and strength of a drug of a manufacturer subject to a value-based purchasing arrangement (as defined in subsection (k)(12)), but only if such manufacturer offers such arrangement to all States.] | ||||
| (C)(iii) | (iii) Application of auditing and recordkeeping requirements | (iii) Application of auditing and recordkeeping requirements | ||
| With respect to a covered entity described in section 256b(a)(4)(L) of this title, any drug purchased for inpatient use shall be subject to the auditing and recordkeeping requirements described in section 256b(a)(5)(C) of this title. | With respect to a covered entity described in section 256b(a)(4)(L) of this title, any drug purchased for inpatient use shall be subject to the auditing and recordkeeping requirements described in section 256b(a)(5)(C) of this title. | |||
| (D) | (D) Limitation on sales at a nominal price | (D) Limitation on sales at a nominal price | ||
§ 1396r–8(k)Definitions(1)–(2)
(c)(1)(D)(i)–(k)(1)(B)(i) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (1)(B)(i)(VI) | (VI) | (VI) | ||
| any reduction in price paid during the rebate period to the manufacturer for a drug by reason of application of part E of subchapter XI; | any reduction in price paid during the rebate period to the manufacturer for a drug by reason of application of part E of subchapter XI; | |||
| (1)(B)(i)(VII) | (VII) | (VII) | ||
| rebates paid by manufacturers under section 1395w–3a(i) of this title; | rebates paid by manufacturers under section 1395w–3a(i) of this title; | |||
| (1)(B)(i)(VIII) | (VIII) | (VIII) | ||
| rebates paid by manufacturers under section 1395w–114b of this title | rebates paid by manufacturers under section 1395w–114b of this title[inserted: ; and] | |||
| (1)(B)(i)(IX) | (IX) [inserted: ] | |||
| [inserted: with respect to a covered outpatient drug that is sold under a value-based purchasing arrangement (as defined in paragraph (12)) during the rebate period, including such a drug that is an inhalation, infusion, instilled, implanted, or injectable drug that is not generally dispensed through a retail community pharmacy—] | ||||
| (1)(B)(i)(IX)(aa) | (aa) [inserted: ] | |||
| [inserted: a refund, rebate, reimbursement, or free goods from the manufacturer or third party on behalf of the manufacturer; or] | ||||
| (1)(B)(i)(IX)(bb) | (bb) [inserted: ] | |||
| [inserted: the withholding or reduction of a payment to the manufacturer or third party on behalf of the manufacturer;] | ||||
| (1)(B)(i)(IX) | [inserted: that is triggered by a patient who fails to achieve outcomes or measures defined under the terms of such value-based purchasing arrangement during the period for which such arrangement is effective.] | |||
| (1)(B)(ii) | (ii) Inclusion of other discounts and payments | (ii) Inclusion of other discounts and payments | ||
| Notwithstanding clause (i), any other discounts, rebates, payments, or other financial transactions that are received by, paid by, or passed through to, retail community pharmacies shall be included in the average manufacturer price for a covered outpatient drug. | Notwithstanding clause (i), any other discounts, rebates, payments, or other financial transactions that are received by, paid by, or passed through to, retail community pharmacies shall be included in the average manufacturer price for a covered outpatient drug. | |||
| (1)(C) | (C) Exclusion of section 505(c) drugs | (C) Exclusion of section 505(c) drugs | ||
| In the case of a manufacturer that approves, allows, or otherwise permits any drug of the manufacturer to be sold under the manufacturer’s new drug application approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(c)], such term shall be exclusive of the average price paid for such drug by wholesalers for drugs distributed to retail community pharmacies. | In the case of a manufacturer that approves, allows, or otherwise permits any drug of the manufacturer to be sold under the manufacturer’s new drug application approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(c)], such term shall be exclusive of the average price paid for such drug by wholesalers for drugs distributed to retail community pharmacies. | |||
| (1)(D) | (D) [inserted: Special rule for certain value-based purchasing arrangements.—] | |||
| [inserted: For purposes of subparagraph (A), in determining the average price paid to a manufacturer for a covered outpatient drug that is sold under a value-based purchasing arrangement (as defined in paragraph (12)) that provides that payment for such drug is made in installments over the course of such arrangement, such price shall be determined as if the aggregate price per the terms of the arrangement were paid in full in the first installment during the rebate period.] | ||||
| (2) | (2) Covered outpatient drug | (2) Covered outpatient drug | ||
| Subject to the exceptions in paragraph (3), the term “covered outpatient drug” means— | Subject to the exceptions in paragraph (3), the term “covered outpatient drug” means— | |||
| (2)(A) | (A) | (A) | ||
| of those drugs which are treated as prescribed drugs for purposes of section 1396d(a)(12) of this title, a drug which may be dispensed only upon prescription (except as provided in paragraph (4)), and— | of those drugs which are treated as prescribed drugs for purposes of section 1396d(a)(12) of this title, a drug which may be dispensed only upon prescription (except as provided in paragraph (4)), and— | |||
§ 1396r–8(k)Definitions(10)–(12)
(k)(2)(A)(i)–(9) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (10) | (10) Retail community pharmacy | (10) Retail community pharmacy | ||
| The term “retail community pharmacy” means an independent pharmacy, a chain pharmacy, a supermarket pharmacy, or a mass merchandiser pharmacy that is licensed as a pharmacy by the State and that dispenses medications to the general public at retail prices. Such term does not include a pharmacy that dispenses prescription medications to patients primarily through the mail, nursing home pharmacies, long-term care facility pharmacies, hospital pharmacies, clinics, charitable or not-for-profit pharmacies, government pharmacies, or pharmacy benefit managers. | The term “retail community pharmacy” means an independent pharmacy, a chain pharmacy, a supermarket pharmacy, or a mass merchandiser pharmacy that is licensed as a pharmacy by the State and that dispenses medications to the general public at retail prices. Such term does not include a pharmacy that dispenses prescription medications to patients primarily through the mail, nursing home pharmacies, long-term care facility pharmacies, hospital pharmacies, clinics, charitable or not-for-profit pharmacies, government pharmacies, or pharmacy benefit managers. | |||
| (11) | (11) Wholesaler | (11) Wholesaler | ||
| The term “wholesaler” means a drug wholesaler that is engaged in wholesale distribution of prescription drugs to retail community pharmacies, including (but not limited to) repackers, distributors, own-label distributors, private-label distributors, jobbers, brokers, warehouses (including distributor’s warehouses, chain drug warehouses, and wholesale drug warehouses) independent wholesale drug traders, and retail community pharmacies that conduct wholesale distributions. | The term “wholesaler” means a drug wholesaler that is engaged in wholesale distribution of prescription drugs to retail community pharmacies, including (but not limited to) repackers, distributors, own-label distributors, private-label distributors, jobbers, brokers, warehouses (including distributor’s warehouses, chain drug warehouses, and wholesale drug warehouses) independent wholesale drug traders, and retail community pharmacies that conduct wholesale distributions. | |||
| (12) | (12) [inserted: Value-Based Purchasing Arrangement.—] | |||
| [inserted: The term “value-based purchasing arrangement” has the meaning given such term in section 447.502 of title 42, Code of Federal Regulations (or any successor regulation).] | ||||